PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent.

Details

Serval ID
serval:BIB_3FB46E47FC22
Type
Article: article from journal or magazin.
Collection
Publications
Title
PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent.
Journal
Interventional cardiology
Author(s)
Byrne R.A., Eeckhout E., Sardella G., Stella P., Verheye S.
ISSN
1756-1477 (Print)
ISSN-L
1756-1485
Publication state
Published
Issued date
05/2017
Peer-reviewed
Oui
Volume
12
Number
1
Pages
13-17
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Patients with diabetes have poor outcomes compared to the general patient population when undergoing percutaneous coronary intervention. The Cre8™ (Alvimedica) drug-eluting stent (DES) has unique features that may improve clinical outcomes in patients with diabetes. These include abluminal reservoir technology, a proprietary polymer-free drug-release system consisting of reservoirs on the stent's outer surface that control and direct drug release exclusively towards the vessel wall, and the Amphilimus™ formulation, which enables enhanced drug tissue permeation, utilising fatty acid transport pathways. This is particularly advantageous in diabetic patients, since increased uptake of fatty acid occurs in diabetic cells. Furthermore, mTOR inhibitors (-limus drugs), which are utilised in DESs, are relatively ineffective in diabetic cells. Clinical efficacy and safety of the Cre8™ in patients with diabetes has been demonstrated in a number of clinical trials and real-world studies, and further studies are on-going.

Keywords
Coronary artery disease, diabetes, drug-eluting stent, percutaneous coronary intervention
Pubmed
Create date
29/03/2018 18:12
Last modification date
20/08/2019 14:37
Usage data